Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Quanterix Corporation
< Previous
1
2
3
Next >
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
May 03, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis
April 22, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients
April 04, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development
March 29, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 23, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
February 09, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology
February 07, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Provides Operational and Preliminary Financial Highlights
January 13, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
November 17, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix’ Simoa® Technology Powers Advances in Alzheimer’s Disease Research Presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 16, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 11, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Co-Inventor of Simoa® David Walt Receives Kabiller Prize in Nanoscience and Nanomedicine
November 08, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based pTau-181 Assay for Alzheimer’s Disease
October 11, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories
September 20, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test
September 13, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix to Host Webinar with Leading Pathologist from Emory Medical Laboratories: “COVID-19 Testing in a Residential University Setting: Implementation, Insights, and Learnings”
September 10, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Releases Statement
August 27, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 09, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021
August 06, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Corporation Releases Operating Results for Second Quarter of 2021
August 05, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Corporation to Release Second Quarter 2021 Financial Results on Aug. 5, 2021
July 28, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Appoints Michael Doyle as Chief Financial Officer
June 28, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Investigation of Plasma Neurofilament Light’s Role in Dementia Diagnosis
June 07, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference and Appear on the June 3 Episode of The Bio Report
June 02, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics
May 11, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Corporation Releases Operating Results for First Quarter 2021
May 05, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Corporation to Release First Quarter 2021 Financial Results on May 5, 2021
April 28, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Appoints Laurie Olson to Board of Directors
April 28, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
Quanterix Webinar: Recent Advancements in Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test for Alzheimer’s Disease
April 22, 2021
From
Quanterix Corporation
Via
Business Wire
Tickers
QTRX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.